All posts by: Michael Zand

Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise
Genetic Engineering & Biotechnology News
Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose …
Merck, looking to build on cancer success, buys IO biotech RigontecFierceBiotech
Merck To Buy RigontecNasdaq
MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-OncologyBusiness Wire (press release)

all 5 news articles »

Patient’s immune status associated with outcome following third …
Medical Xpress
Treatment with third-generation CAR T–cell therapy led to a complete response in six of 15 patients with a CD19-positive B-cell malignancy and overall survival …
Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy …Doctors Lounge

all 2 news articles »

Patient’s immune status associated with outcome following third-generation CAR T-cell therapy
Medical Xpress
Treatment with third-generation CAR T–cell therapy led to a complete response in six of 15 patients with a CD19-positive B-cell malignancy and overall survival was associated with the patient’s immune status, according to data from a phase I/IIa …

Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release …
Nasdaq
“The clinical success and recent regulatory approval of the first CAR T-cell therapy has shown the efficacy of CAR T-cell technologies in hematological malignancies and the potential promise of the treatment in solid tumors as well. However, these …
Poseida Therapeutics Presents Novel BCMA-Specific CAR–T Therapy at CAR-TCR SummitEconoTimes

all 2 news articles »

Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release …
GlobeNewswire (press release)
“The clinical success and recent regulatory approval of the first CAR T-cell therapy has shown the efficacy of CAR T-cell technologies in hematological malignancies and the potential promise of the treatment in solid tumors as well. However, these …
Poseida Therapeutics Presents Novel BCMA-Specific CAR–T Therapy at CAR-TCR SummitEconoTimes

all 2 news articles »

Voyager Therapeutics gene therapy improves motor function in Parkinson’s patients
STAT
gene therapy from Voyager Therapeutics (VYGR ¹) delivered surgically into the brains of patients with advanced Parkinson’s disease reduced their need for standard Parkinson’s medications and improved motor function, according to results from a small, …
Voyager Therapeutics posts added proof its gene therapy for Parkinson’s can workEndpoints News
Voyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced …GlobeNewswire (press release)
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Closed Well Above Its 50 Day Moving AverageFirst News 24

all 26 news articles »

Voyager Therapeutics adds proof its gene therapy for Parkinson’s can work, shares soar
Endpoints News
The Cambridge, MA-based biotech has fleshed out its early-stage proof-of-concept data on VY-AADC01, offering new data that demonstrate a heightened efficacy for two higher doses of the gene therapy. Executives at Voyager tell me that they’re heartened …
Voyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced …GlobeNewswire (press release)
Voyager Therapeutics (VYGR) Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced …StreetInsider.com
Voyager’s VY-AADC01 shows encouraging results in early-stage Parkinson’s study; shares ahead 27% premarketSeeking Alpha

all 30 news articles »